Evidence map›Paper›PMID 40492125›Full record

ArticleFrontiers in oncology2025

Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma.

Benjamin Stubbe, Malene P Stoico, Simone K Terp, Poul H Madsen, Søren Lundbye-Christensen, Carsten P Hansen, Laurids Ø Poulsen, Louise S Rasmussen, Mette N Yilmaz, Lars H Jensen and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Benjamin StubbeDepartment of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark.
Malene P StoicoDepartment of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
Simone K TerpDepartment of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
Poul H MadsenClinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Søren Lundbye-ChristensenDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Carsten P HansenDepartment of Surgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Laurids Ø PoulsenDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Louise S RasmussenDepartment of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Mette N YilmazDepartment of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Lars H JensenDepartment of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.
Torben F HansenDepartment of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.
Per PfeifferDepartment of Medical Oncology, Odense University Medical Center, University of Odense, Odense, Denmark.
Anders C LarsenDepartment of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark.
Henrik B KrarupClinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Inge S PedersenDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Jane P HasselbyDepartment of Pathology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Astrid Z JohansenDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Inna M ChenDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Julia S JohansenDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Ole Thorlacius-UssingDepartment of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark.
Stine D HenriksenDepartment of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metastatic pancreatic ductal adenocarcinoma (PDAC) is highly lethal. Promoter hypermethylation of SFRP1 (phSFRP1) in cell-free DNA is an established prognostic biomarker in PDAC. We used digital droplet PCR (ddPCR) to examine whether the prognostic impact of phSFRP1 was allele fraction (AF) dependent. Methods: Prospectively collected plasma samples were analyzed blinded. Dual-strand methylation ddPCR assays were designed for SFRP1, with single-strand assay for the reference gene EPHA3. Patients were stratified into unmethylated SFRP1 (umSFRP1), low phSFRP1 AF (phSFRP1 Results: Overall, 354 patients were included. Patients with umSFRP1 ( Discussion: Patients with phSFRP1

Indexed as

biomarkerepigeneticsliquid biopsymethylationpancreatic ductal adenocarcinomaSfrp1

Identifiers

PMID40492125
PMCPMC12146188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.